DG, you are most likely correct about a slow process for Vitaros to roll out and gain traction, given the complexity of the product and patients using it, instead of looking for a blockbuster right away
I'm now just looking to see if Vitaros can pay the bills, until 2 great products with unmet need can prove themselves in the clinic, Femprox, a blockbuster, and Rayva.
Rayva has a $100M USA sales potential, an unmet need, no competition and a specialty market that APRI could sell to themselves. Also APRI spoke about out licensing Rayva ex-US, if they need cash I would start that process in a few places right away to generate some cash.
Also I would look to out licence NexAct, and to get more products moving like Mycova, and a PE product, both of which have good patent protection. There's also Vitaros in Latin America they can out license for some up-fronts, most likely room temp there though so that may be a ways off.
Also once Vitaros launches in Canada, Germany and France, there'll be alot more sales to look at as you mentioned before.
Market Data 
Markets 
AI
